Kawano Y, Takaue Y, Watanabe T, Ninomiya T, Kuroda Y, Nissen C, Gratwohl A, Speck B
Rinsho Ketsueki. 1989 Mar;30(3):327-31.
The lymphocytotoxicity and mitogenicity between six different ALG preparations on the clinical use world wide were compared. No significant difference in the lympholytic activity was observed between preparations and 100% cell lysis was achieved at a concentration of 50 micrograms/ml in the presence of complement. On the other hand, four preparations now in use in European countries and USA showed variable mitogenic activities on lymphocytes in the absence of complement, whereas two ALGs used in Japan did not. As the stimulatory effects of ALG on lymphocytes may contribute to the clinical outcome in the treatment of severe aplastic anemia (Kawano et al, 1988), these date can explain the poor clinical results of ALG therapy with those two preparations in Japan. Careful measures should be paid in the construction of treatment protocol and selection of ALG preparations to yield the best results.
比较了全球临床使用的六种不同抗淋巴细胞球蛋白(ALG)制剂之间的淋巴细胞毒性和促有丝分裂活性。各制剂之间未观察到淋巴细胞溶解活性的显著差异,在有补体存在的情况下,浓度为50微克/毫升时可实现100%细胞裂解。另一方面,目前在欧洲国家和美国使用的四种制剂在无补体的情况下对淋巴细胞显示出不同的促有丝分裂活性,而日本使用的两种ALG则没有。由于ALG对淋巴细胞的刺激作用可能有助于重型再生障碍性贫血治疗的临床结果(Kawano等人,1988年),这些数据可以解释日本使用这两种制剂进行ALG治疗的临床效果不佳的原因。在制定治疗方案和选择ALG制剂时应谨慎采取措施,以取得最佳效果。